21.43
03-January-25 16:45:00
15 minutes delayed
Stocks
+0.79
+3.83%
Today's range
20.68 - 21.85
ISIN
N/A
Source
NASDAQ
Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD)
08 Jan 2024 07:00:00 By Nasdaq GlobeNewswire
Tourmaline Bio added to the NASDAQ Biotechnology Index
15 Dec 2023 16:00:00 By Nasdaq GlobeNewswire
Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board
14 Dec 2023 07:30:00 By Nasdaq GlobeNewswire